Literature DB >> 25877468

Combining immunotherapy with radiation for the treatment of glioblastoma.

Kevin K H Chow1, Wendy Hara, Michael Lim, Gordon Li.   

Abstract

Glioblastoma is a devastating cancer with universally poor outcomes in spite of current standard multimodal therapy. Immunotherapy is an attractive new treatment modality given its potential for exquisite specificity and its favorable side effect profile; however, clinical trials of immunotherapy in GBM have thus far shown modest benefit. Optimally combining radiation with immunotherapy may be the key to unlocking the potential of both therapies given the evidence that radiation can enhance anti-tumor immunity. Here we review this evidence and discuss considerations for combined therapy.

Entities:  

Mesh:

Year:  2015        PMID: 25877468     DOI: 10.1007/s11060-015-1762-9

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  55 in total

1.  Radiotherapy enhances antitumor effect of anti-CD137 therapy in a mouse Glioma model.

Authors:  Elizabeth W Newcomb; Yevgeniy Lukyanov; Noriko Kawashima; Michelle Alonso-Basanta; Shu-Chi Wang; Mengling Liu; Maria Jure-Kunkel; David Zagzag; Sandra Demaria; Silvia C Formenti
Journal:  Radiat Res       Date:  2010-04       Impact factor: 2.841

2.  Fas ligand expression and depletion of T-cell infiltration in astrocytic tumors.

Authors:  M Ichinose; J Masuoka; T Shiraishi; T Mineta; K Tabuchi
Journal:  Brain Tumor Pathol       Date:  2001       Impact factor: 3.298

3.  TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.

Authors:  Courtney A Crane; Seunggu J Han; Jeffery J Barry; Brian J Ahn; Lewis L Lanier; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2009-11-05       Impact factor: 12.300

4.  Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy.

Authors:  June L Chan; Susan W Lee; Benedick A Fraass; Daniel P Normolle; Harry S Greenberg; Larry R Junck; Stephen S Gebarski; Howard M Sandler
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

5.  Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery.

Authors:  M D Walker; S B Green; D P Byar; E Alexander; U Batzdorf; W H Brooks; W E Hunt; C S MacCarty; M S Mahaley; J Mealey; G Owens; J Ransohoff; J T Robertson; W R Shapiro; K R Smith; C B Wilson; T A Strike
Journal:  N Engl J Med       Date:  1980-12-04       Impact factor: 91.245

Review 6.  Focus on TILs: Prognostic significance of tumor infiltrating lymphocytes in human glioma.

Authors:  Gavin P Dunn; Ian F Dunn; William T Curry
Journal:  Cancer Immun       Date:  2007-08-13

7.  Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis.

Authors:  Sabine Wintterle; Bettina Schreiner; Meike Mitsdoerffer; Dagmar Schneider; Lieping Chen; Richard Meyermann; Michael Weller; Heinz Wiendl
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

8.  Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

Authors:  Eric A Reits; James W Hodge; Carla A Herberts; Tom A Groothuis; Mala Chakraborty; Elizabeth K Wansley; Kevin Camphausen; Rosalie M Luiten; Arnold H de Ru; Joost Neijssen; Alexander Griekspoor; Elly Mesman; Frank A Verreck; Hergen Spits; Jeffrey Schlom; Peter van Veelen; Jacques J Neefjes
Journal:  J Exp Med       Date:  2006-04-24       Impact factor: 14.307

Review 9.  The future of glioblastoma therapy: synergism of standard of care and immunotherapy.

Authors:  Mira A Patel; Jennifer E Kim; Jacob Ruzevick; Gordon Li; Michael Lim
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

Review 10.  Current vaccine trials in glioblastoma: a review.

Authors:  Linda W Xu; Kevin K H Chow; Michael Lim; Gordon Li
Journal:  J Immunol Res       Date:  2014-04-03       Impact factor: 4.818

View more
  6 in total

1.  CCR2 inhibition reduces tumor myeloid cells and unmasks a checkpoint inhibitor effect to slow progression of resistant murine gliomas.

Authors:  Joseph A Flores-Toro; Defang Luo; Adithya Gopinath; Matthew R Sarkisian; James J Campbell; Israel F Charo; Rajinder Singh; Thomas J Schall; Meenal Datta; Rakesh K Jain; Duane A Mitchell; Jeffrey K Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-26       Impact factor: 11.205

Review 2.  The role of radiation in treating glioblastoma: here to stay.

Authors:  Christopher D Corso; Ranjit S Bindra; Minesh P Mehta
Journal:  J Neurooncol       Date:  2017-03-07       Impact factor: 4.130

Review 3.  Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies.

Authors:  Neil M D'Souza; Penny Fang; Jennifer Logan; Jinzhong Yang; Wen Jiang; Jing Li
Journal:  Front Oncol       Date:  2016-10-07       Impact factor: 6.244

Review 4.  Current Advances in Checkpoint Inhibitors: Lessons from Non-Central Nervous System Cancers and Potential for Glioblastoma.

Authors:  Natasha Lakin; Robert Rulach; Stefan Nowicki; Kathreena M Kurian
Journal:  Front Oncol       Date:  2017-07-06       Impact factor: 6.244

Review 5.  An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.

Authors:  Martha R Neagu; David A Reardon
Journal:  Curr Treat Options Oncol       Date:  2015-11

Review 6.  Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.

Authors:  Joshua R D Pearson; Stefania Cuzzubbo; Simon McArthur; Lindy G Durrant; Jason Adhikaree; Chris J Tinsley; A Graham Pockley; Stephanie E B McArdle
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.